Standard BioTools Director Adds New Equity Awards; Total Stake Tops 79 M Shares

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) Form 4 filing dated 06/24/2025 details new equity awards granted to director and ≥10% shareholder Eli Casdin.

• Restricted Stock Units (RSUs): 94,592 RSUs awarded on 06/20/2025; they vest in full on the earlier of 06/20/2026 or one day prior to the next annual meeting, conditional on continued service. Each RSU converts into one common share.
• Stock Options: Option covering 125,660 shares with a $1.05 exercise price, granted 06/20/2025. The option vests in 12 equal monthly installments beginning 07/20/2025 and expires 06/20/2035.
• Post-transaction ownership: 2,901,062 shares held directly. Through affiliated investment funds, Casdin controls an additional 76,075,636 shares (13,939,637 via Casdin Private Growth Equity Fund II, 2,744,219 via Casdin Private Growth Equity Fund, and 59,391,780 via Casdin Partners Master Fund).
• Role: Casdin is both a director and ≥10% beneficial owner, indicating significant ongoing influence.

No purchase or sale of shares occurred; the awards were granted at no cost, reflecting routine director compensation and aligning incentives with shareholders. The filing does not disclose any earnings data, cash consideration, or changes to company guidance.

Insights

Senior Securities Analyst

TL;DR: Routine equity grants; confirms large insider stake, minimal immediate valuation impact.

The Form 4 shows a standard mix of RSUs and stock options issued to Eli Casdin. With over 79 million shares already under his control (direct and indirect), the additional 94.6 K RSUs and 125.7 K options represent <1% incremental ownership, so dilution is immaterial. Because awards vest over time and options are struck at $1.05, they primarily serve to maintain incentive alignment rather than signal a directional view. No open-market buying or selling occurred, so the filing offers limited insight into insider sentiment. For investors, the key takeaway is simply that Casdin retains—and marginally increases—his already substantial position, reinforcing governance continuity but not altering the investment thesis.

Corporate Governance Specialist

TL;DR: Standard director compensation; sustains board-level alignment, governance status quo.

Equity compensation structured as full-value RSUs plus monthly-vesting options is common for directors of small-cap life-science firms. Vesting tied to service and a 10-year option life are conventional. The disclosure reiterates that Casdin, via multiple funds, is a control shareholder; investors should note possible related-party considerations but nothing in the filing signals governance changes. No 10b5-1 plan was indicated for these grants. Overall governance impact: neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Casdin Eli

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		A		94,592(1)	A	$0	2,901,062	D
Common Stock								13,939,637	I	Casdin Private Growth Equity Fund II, L.P.(2)
Common Stock								2,744,219	I	By Casdin Private Growth Equity Fund, L.P.(3)
Common Stock								59,391,780	I	Casdin Partners Master Fund, L.P(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.05	06/20/2025		A		125,660		(5)	06/20/2035	Common Stock	125,660	$0	125,660	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

3. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

4. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.

5. The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

	/s/ Eli Casdin by Tomone Tanaka, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Standard BioTools (LAB) shares did Eli Casdin receive in the latest Form 4?

The filing reports 94,592 RSUs and an option for 125,660 shares granted on 06/20/2025.

What is the exercise price and term of the new LAB stock option?

The option is exercisable at $1.05 per share and expires on 06/20/2035.

When do the RSUs granted to Eli Casdin vest?

They vest in full on 06/20/2026 or one day before the next annual meeting, whichever comes first.

What is Eli Casdin’s total beneficial ownership in Standard BioTools after this filing?

Following the grant, he controls 2,901,062 shares directly and 76,075,636 shares indirectly through affiliated funds.

Did the Form 4 indicate any open-market buying or selling by Eli Casdin?

No. The reported transactions are equity awards; there were no purchases or sales of existing shares.